Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021

Rhea-AI Summary

Cortexyme, Inc. (Nasdaq: CRTX) announced that CEO Casey Lynch will participate in a virtual fireside chat at the Stifel 3rd Annual CNS Day on April 1, 2021, at 10:00 a.m. EDT. This event coincides with the company's ongoing Phase 2/3 GAIN Trial for its lead therapeutic candidate, atuzaginstat, aimed at treating Alzheimer’s disease. Topline data from the trial is expected in Q4 2021. The webcast will be available on the Cortexyme investor site and archived for 90 days.

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, co-founder, and chair, will participate in a fireside chat at the Stifel 3^rd Annual CNS Day, a virtual event, on Thursday, April 1, 2021, at 10:00 a.m. EDT / 7:00 a.m. PDT.

A live webcast of the fireside chat will be accessible on the Investor Calendar page under the News & Events heading of the Cortexyme investor site (ir.cortexyme.com). The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005483/en/

FAQ

When is Cortexyme's virtual fireside chat at Stifel 3rd Annual CNS Day?

Cortexyme's virtual fireside chat is scheduled for April 1, 2021, at 10:00 a.m. EDT.

Who will participate in the fireside chat at the Stifel event?

CEO Casey Lynch will participate in the fireside chat.

What is the focus of Cortexyme's ongoing GAIN Trial?

The GAIN Trial focuses on testing atuzaginstat for patients with mild to moderate Alzheimer's disease.

When is Cortexyme expecting topline data from the GAIN Trial?

Topline data from the GAIN Trial is expected in the fourth quarter of 2021.

Where can I access the live webcast of Cortexyme's fireside chat?

The live webcast can be accessed on the Cortexyme investor site under the News & Events section.